XOMA Corporation (NASDAQ:XOMA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday, November 2nd.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
Other equities research analysts have also issued research reports about the stock. ValuEngine upgraded shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of XOMA Corporation in a research note on Thursday, August 10th. Finally, Wedbush reiterated a “hold” rating on shares of XOMA Corporation in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $30.00.
Shares of XOMA Corporation (NASDAQ XOMA) opened at $27.00 on Thursday. XOMA Corporation has a one year low of $3.96 and a one year high of $33.00. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 3.53.
TRADEMARK VIOLATION NOTICE: This piece was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/xoma-corporation-xoma-lowered-to-hold-at-zacks-investment-research/1751007.html.
A number of institutional investors and hedge funds have recently made changes to their positions in XOMA. EAM Investors LLC bought a new position in XOMA Corporation in the third quarter valued at approximately $835,000. OxFORD Asset Management LLP acquired a new position in XOMA Corporation during the third quarter worth $543,000. Finally, California Public Employees Retirement System increased its holdings in XOMA Corporation by 95.5% during the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock worth $123,000 after buying an additional 10,640 shares during the last quarter. 30.69% of the stock is currently owned by hedge funds and other institutional investors.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with our FREE daily email newsletter.